Cargando…
Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes
Antigen-specific immunotherapy is an appealing strategy to preserve beta-cell function in type 1 diabetes, although the approach has yet to meet its therapeutic endpoint. Direct administration of autoantigen into lymph nodes has emerged as an alternative administration route that can improve the eff...
Autores principales: | Barcenilla, Hugo, Pihl, Mikael, Wahlberg, Jeanette, Ludvigsson, Johnny, Casas, Rosaura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791064/ https://www.ncbi.nlm.nih.gov/pubmed/35095874 http://dx.doi.org/10.3389/fimmu.2021.797172 |
Ejemplares similares
-
Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes
por: Tavira, Beatriz, et al.
Publicado: (2018) -
Cellular and Humoral Immune Responses in Type 1 Diabetic Patients Participating in a Phase III GAD-alum Intervention Trial
por: Axelsson, Stina, et al.
Publicado: (2013) -
Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD(65)-induced immune response
por: Tavira, Beatriz, et al.
Publicado: (2017) -
Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2
por: Nowak, Christoph, et al.
Publicado: (2022) -
Long-Lasting Immune Responses 4 Years after GAD-Alum Treatment in Children with Type 1 Diabetes
por: Axelsson, Stina, et al.
Publicado: (2011)